Pertuzumab

【Product name】Perjeta

[English common name]Pertuzumab

[Chinese common name]Pertuzumab

[English name]Ertuzumab [INN], Omnitarg, rhuMAb 2C4

[Chinese other name]

[Indications] PERJETA is a HER2/neu receptor antagonist that should be combined with trastuzumab and docetaxel. The treatment population is: no previous anti-HER2 treatment or chemotherapy. HER2+ metastaticBreast cancerpatient.

【Dosage】
(1) Intravenous infusion only. Do not administer intravenous bolus or bolus.
(2) The initial dose was 840 mg, and the intravenous infusion was completed over 60 minutes. Thereafter, 420 mg every 3 weeks, intravenous infusion over a period of 30 to 60 minutes.

[Storage]Protected from light and stored in the refrigerator at 2 ° C to 8 ° C (36 ° F to 46 ° F).

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.